eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Journal's reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
3/2021
vol. 38
 
Share:
Share:
more
 
 
abstract:
Original paper

The comparison of fluticasone propionate/formoterol with fluticasone propionate/salmeterol for paediatric asthma: a meta-analysis of randomized controlled trials

Xiaofen Jin
1
,
Lianfang Wu
2
,
Ji Wang
3
,
Malong Feng
3

1.
Department of Pediatrics, Fenghua District People’s Hospital of Ningbo, Zhejiang, China
2.
Department of Pediatrics, Ningbo Yinzhou Second Hospital, Zhejiang, China
3.
Department of Respiration, Fenghua District People’s Hospital of Ningbo, Zhejiang, China
Adv Dermatol Allergol 2021; XXXVIII (3): 377–383
Online publish date: 2020/01/31
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
The comparison of fluticasone propionate/formoterol (FP/FORM) with fluticasone propionate/salmeterol (FP/SAL) for paediatric asthma remains controversial. Aim: We conduct a systematic review and meta-analysis to explore the efficacy and safety of FP/FORM versus FP/SAL for paediatric asthma.

Material and methods
We have searched PubMed, Embase, Web of science, EBSCO, and Cochrane library databases through August 2019 for randomized controlled trials (RCTs) assessing the effect of FP/FORM versus FP/SAL for paediatric asthma. This meta-analysis is performed using the random-effects model.

Results
Three RCTs are included in the meta-analysis. Overall for paediatric asthma, FP/FORM and FP/SAL demonstrate a comparable influence on FEV1 (Std. MD = –0.01; 95% CI: –0.04 to 0.03; p = 0.62), FVC (Std. MD = 0; 95% CI: –0.07 to 0.06; p = 0.87), FEF25 (Std. MD = –1.69; 95% CI: –6.69 to 3.31; p = 0.51), FEF50 (Std. MD = 0.10; 95% CI: –0.12 to 0.33; p = 0.37), FEF75 (Std. MD = 0.01; 95% CI: –0.21 to 0.24; p = 0.91), asthma symptom scores (Std. MD = –0.03; 95% CI: –0.11 to 0.04; p = 0.43), sleep disturbance scores (Std. MD = 0.03; 95% CI: –0.19 to 0.24; p = 0.81) and adverse events (RR = 1.07; 95% CI: 0.83 to 1.38; p = 0.61).

Conclusions
FP/FORM and FP/SAL show a comparable efficacy for paediatric asthma.

keywords:

fluticasone propionate/formoterol, propionate/salmeterol, paediatric asthma, randomized controlled trials, meta-analysis

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe